+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Alpha Antitrypsin Deficiency (AATD)- Market Insights, Epidemiology and Market Forecast-2030

  • ID: 4085564
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 200 pages
  • DelveInsight

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • CSL Behring
  • Dicerna Pharmaceuticals
  • Grifols
  • Inhibrx
  • Kamada
  • MORE
‘Alpha Antitrypsin Deficiency (AATD)- Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AATD's in the United States and EU5 (Germany, Spain, Italy, France and United Kingdom).

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Alpha Antitrypsin Deficiency (AATD) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017-2030

Alpha Antitrypsin Deficiency (AATD) - Disease Understanding and Treatment Algorithm

Alpha Antitrypsin Deficiency (AATD) occurs when the body is unable to produce sufficient amounts of AAT protein, exposing the organs to harmful effects of proteolytic enzymes, such as neutrophil elastase. AAT protein, a protein made in the liver, plays an important role in protecting organs of the body such lungs from proteolytic enzymes, but some causes lead the protein to be unable to enter the bloodstream and work as desired, leading to increased risk of lung disease.

The Alpha Antitrypsin Deficiency (AATD) market report gives the thorough understanding of the AATD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Alpha Antitrypsin Deficiency in the US and Europe.

Alpha Antitrypsin Deficiency Epidemiology

The Alpha Antitrypsin Deficiency (AATD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 6 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of AATD, total diagnosed population of AATD, genotype of AATD diagnosed pool and comorbidities associated with AATD) scenario of Alpha Antitrypsin Deficiency (AATD) in the 6MM covering United States and EU5 countries (Germany, Spain, Italy, France and United Kingdom) from 2017-2030.

According to the publisher, the total number of prevalent cases of Alpha Antitrypsin Deficiency (AATD) in 6 MM was found to be 175,009, in the year 2017. 

Alpha Antitrypsin Deficiency Drug Chapters

This segment of the Alpha Antitrypsin Deficiency report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Current treatment for AATD includes both medicinal and surgical therapies. Both of these categories rely on providing symptomatic relief to the subjects based on the level and severity of their conditions. Commonly used therapy for AATD is similar to chronic obstructive pulmonary disease (COPD) and emphysema treatment: abstinence from smoking, long-acting bronchodilators, antibiotics, inhalations of corticosteroids, and long-acting beta-agonists are recommended. However, the application of such solutions does not increase the functional AAT level in serum. The only currently approved and dedicated treatment for AATD is Augmentation therapy. Weekly intravenous supplementation with the AAT protein purified from pooled healthy donors' plasma that has become available since the end of the 1980s. It is based on the administration of the purified human AAT at a dose of 60  mg/kg per week in order to achieve the protective level of AAT in serum.

Alpha Antitrypsin Deficiency Market Outlook

The Alpha Antitrypsin Deficiency market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, the market of Alpha Antitrypsin Deficiency in 6MM was found to be USD 698 Million in 2017, and is expected to increase during the course of the study period (2017-2030). Among the 6MM, the United States accounts for the largest market size of AATD, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain).

Alpha Antitrypsin Deficiency Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Alpha Antitrypsin Deficiency Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Alpha Antitrypsin Deficiency Report Key Strengths
  • 11 Year Forecast
  • 6MM Coverage
- Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Alpha Antitrypsin Deficiency Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Alpha Antitrypsin Deficiency market
  • Organize sales and marketing efforts by identifying the best opportunities for Alpha Antitrypsin Deficiency market
  • To understand the future market competition in the Alpha Antitrypsin Deficiency market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alnylam Pharmaceuticals
  • CSL Behring
  • Dicerna Pharmaceuticals
  • Grifols
  • Inhibrx
  • Kamada
  • MORE
1 Key Insights

2 Executive Summary of Alpha Antitrypsin Deficiency

3 SWOT Analysis for Alpha Antitrypsin Deficiency

4 Patient Share of Alpha Antitrypsin Deficiency at a Glance
4.1 Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2017
4.2 Prevalent Cases (%) Distribution of Alpha Antitrypsin Deficiency in 2030

5 Alpha Antitrypsin Deficiency Market Overview at a Glance
5.1 Market Share (%) Distribution of Alpha Antitrypsin Deficiency in 2017
5.2 Market Share (%) Distribution of Alpha Antitrypsin Deficiency in 2030

6 Disease Background and Overview
6.1 Introduction
6.2 Symptoms
6.3 Etiology
6.4 Risk Factors
6.5 Genetic Inheritance of AAT Deficiency
6.6 Clinical Manifestations
6.7 Pathophysiology
6.8 Biomarkers
6.9 Diagnosis
6.1 Diagnostic Delay

7 Epidemiology and Patient Population
7.1 Key Findings
7.2 Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM

8 Country-wise Epidemiology of Alpha-1-Antitrypsin Deficiency
8.1 Assumptions and Rationale: 6MM
8.2 United States
8.2.1 Prevalence of Symptomatic AATD in the United States
8.2.2 Diagnosed population of AATD in the United States
8.2.3 Genotype of AATD Diagnosed patients in the United States
8.2.4 Comorbidity associated with AATD in the United States
8.3 EU5
8.3.1 Germany
8.3.1.1 Prevalence of Symptomatic AATD in Germany
8.3.1.2 Diagnosed population of AATD in Germany
8.3.1.3 Genotype of AATD Diagnosed patients in Germany
8.3.1.4 Comorbidity associated with AATD in Germany
8.3.2 France
8.3.2.1 Prevalence of Symptomatic AATD in France
8.3.2.2 Diagnosed population of AATD in France
8.3.2.3 Genotype of AATD Diagnosed patients in France
8.3.2.4 Comorbidity associated with AATD in France
8.3.3 Italy
8.3.3.1 Prevalence of Symptomatic AATD in Italy
8.3.3.2 Diagnosed population of AATD in Italy
8.3.3.3 Genotype of AATD Diagnosed patients in Italy
8.3.3.4 Comorbidity associated with AATD in Italy
8.3.4 Spain
8.3.4.1 Prevalence of Symptomatic AATD in Spain
8.3.4.2 Diagnosed population of AATD in Spain
8.3.4.3 Genotype of AATD Diagnosed patients in Spain
8.3.4.4 Comorbidity associated with AATD in Spain
8.3.5 United Kingdom
8.3.5.1 Prevalence of Symptomatic AATD in the United Kingdom
8.3.5.2 Diagnosed population of AATD in the United Kingdom
8.3.5.3 Genotype of AATD Diagnosed patients in the United Kingdom
8.3.5.4 Comorbidity associated with AATD in the United Kingdom

9 Treatment
9.1 Current therapies
9.1.1 Augmentation Therapy
9.1.2 Gene Therapy strategies
9.1.3 Lifestyle Changes
9.1.4 Novel therapeutics

10 Treatment Algorithm
10.1 Management of Alpha-Antitrypsin (AAT) Deficiency with Lung Disease
10.2 Management of Alpha-Antitrypsin (AAT) Deficiency with Liver Disease

11 Unmet Needs

12 Organizations contributing toward Alpha Antitrypsin Deficiency

13 Case Reports
13.1 An unusual case of alpha-1-antitrypsin deficiency: SZ/Z
13.2 The Importance of Early Identification of Alpha-1 Antitrypsin Deficiency
13.3 A New SERPINA-1 Missense Mutation Associated with Alpha-1 Antitrypsin Deficiency and Bronchiectasis

14 Marketed Drugs
14.1 Prolastin C: Grifols
14.1.1 Drug Description
14.1.2 Mechanism of Action
14.1.3 Regulatory Milestones
14.1.4 Advantages and Disadvantages
14.1.5 Safety and Efficacy of Prolastin-C
14.2 Glassia: Kamada
14.2.1 Drug Description
14.2.2 Mechanism of Action
14.2.3 Regulatory Milestones
14.2.4 Advantages and Disadvantages
14.2.5 Safety and Efficacy of Glassia
14.3 Aralast: Shire
14.3.1 Drug Description
14.3.2 Mechanism of Action
14.3.3 Regulatory Milestones
14.3.4 Advantages and Disadvantages
14.3.5 Safety and Efficacy of Aralast
14.4 Zemaira: CSL Behring
14.4.1 Drug Description
14.4.2 Mechanism of Action
14.4.3 Regulatory Milestones
14.4.4 Advantages and Disadvantages
14.4.5 Safety and Efficacy of Zemaira
14.5 Alfalastin: LFB Biotechnologies
14.5.1 Description
14.5.2 Regulatory Milestones
14.5.3 Advantages and Disadvantages
14.5.4 Safety and Efficacy
14.6 Trypsone: Grifols
14.6.1 Description
14.6.2 Regulatory Milestones
14.6.3 Advantages and Disadvantages
14.6.4 Efficacy and Safety

15 Emerging Therapies
15.1 Inhaled AAT (Glassia IH): Kamada Ltd
15.1.1 Product Description
15.1.2 Regulatory Milestones
15.1.3 Product Development Activities
15.1.4 Clinical Development
15.1.4.1 Clinical Trials Information
15.1.5 Safety and Efficacy
15.2 ALN-AAT02: Alnylam Pharmaceuticals
15.2.1 Product Description
15.2.2 Product Development Activities
15.2.3 Clinical development
15.2.3.1 Clinical Trials Information
15.2.4 Safety and Efficacy
15.3 ARO-AAT: Arrow Head Pharmaceuticals
15.3.1 Product Description
15.3.2 Product Development Activities
15.3.3 Clinical Development
15.3.3.1 Clinical Trials Information
15.3.4 Safety and Efficacy
15.4 VX-814: Vertex Pharmaceuticals
15.4.1 Product Description
15.4.2 Product Development Activities
15.4.3 Clinical Development
15.4.3.1 Clinical Trials Information
15.5 Alvelestat (MPH-966): Mereo Biopharma
15.5.1 Product Description
15.5.2 Product Development Activities
15.5.3 Clinical Development
15.5.3.1 Clinical Trials Information
15.6 DCR-A1AT: Dicerna Pharmaceuticals
15.6.1 Product Description
15.6.2 Product Development Activities
15.6.3 Clinical Development
15.6.3.1 Clinical Trial Information
15.6.4 Pre-clinical Results

16 Other Promising Candidates
16.1 INBRX-101: Inhibrx
16.1.1 Product Description
16.1.2 Product Development Activities
16.1.3 Clinical development
16.2 Carbamazepine: Novartis Pharmaceuticals
16.2.1 Product Description
16.2.2 Clinical Development
16.2.2.1 Clinical Trials Information
16.3 VX-864: Vertex Pharmaceuticals
16.3.1 Product Description

17 Alpha Antitrypsin Deficiency: 6 Major Market Analysis
17.1 Total Market Size of AATD

18 Alpha Antitrypsin Deficiency: Country-Wise Market Analysis
18.1 United States
18.1.1 Total Market Size of AATD
18.1.2 Market Size of Alpha Antitrypsin Deficiency by Therapies in United States
18.2 EU-5
18.2.1 Germany
18.2.1.1 Total Market Size of AATD in Germany
18.2.1.2 Market Size of Alpha Antitrypsin Deficiency by Therapies in Germany
18.2.2 France
18.2.2.1 Total Market Size of AATD in France
18.2.2.2 Market Size of Alpha Antitrypsin Deficiency by Products in France
18.2.3 Italy
18.2.3.1 Total Market Size of AATD in Italy
18.2.3.2 Market Size of Alpha Antitrypsin Deficiency by Products in Italy
18.2.4 Spain
18.2.4.1 Total Market Size of AATD in Spain
18.2.4.2 Market Size of Alpha Antitrypsin Deficiency by Products in Spain
18.2.5 United Kingdom
18.2.5.1 Total Market Size of AATD in The UK
18.2.5.2 Market Size of Alpha Antitrypsin Deficiency by Products in UK

19 Grifols Initiatives towards Alpha Antitrypsin deficiency

20 US FDA Initiatives for patients with Alpha-1 Antitrypsin Deficiency (AATD)

21 Market Drivers

22 Market Barriers

23 Access and Reimbursement Overview of Alpha Antitrypsin Deficiency
23.1 The Italian Experience
23.2 Augmentation Therapy - slowly finding its way in the UK
23.3 The Changing Future

24 Appendix
24.1 Bibliography
24.2 Report Methodology

25 Capabilities

26 Disclaimer

27 About the Publisher
Note: Product cover images may vary from those shown
  • Grifols
  • Kamada
  • Shire
  • CSL Behring
  • LFB Biotechnologies
  • Alnylam Pharmaceuticals
  • Arrow Head Pharmaceuticals
  • Vertex Pharmaceuticals
  • Mereo Biopharma
  • Dicerna Pharmaceuticals
  • Inhibrx
  • Vertex Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll